Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a CB2 agonist, a CB2 partial agonist, or a CB2 positive allosteric modulator. In preferred embodiments, the CB2 target agent is dimethyl heptyl cannabidiol (CBD-DMH), while the cannabimimetic agent is selected from the group consisting of ?8-tetrahydrocannabinol (?8-THC), ?9-tetrahydrocannabinol, (?9-THC), CP55940, and WIN55212-2.